PDL BioPharma, Inc acquires, manages, and commercializes commercial stage pharmaceutical assets and late clinical stage pharmaceutical products in the United States, Europe, and internationally. The company operates in three segments: Pharmaceutical, Medical Devices, and Income Generating Assets. The Pharmaceutical segment manufactures, markets, and sells prescription medicine products for the treatment of hypertension to wholesalers under the Tekturna and Tekturna HCT names in the United States, as well as under the Rasilez and Rasilez HCT names internationally.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone775-832-8500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$198.11 million
Profitability
Miscellaneous
Employees105
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
PDL BioPharma (NASDAQ:PDLI) Frequently Asked Questions
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma announced that its Board of Directors has approved a stock buyback plan on Monday, September 24th 2018, which permits the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 27.3% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's board believes its stock is undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma Inc (NASDAQ:PDLI) posted its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The biotechnology company earned ($22.53) million during the quarter. PDL BioPharma had a positive return on equity of 6.61% and a negative net margin of 32.13%. View PDL BioPharma's Earnings History.
When is PDL BioPharma's next earnings date?
What price target have analysts set for PDLI?
1 Wall Street analysts have issued 1 year price objectives for PDL BioPharma's shares. Their predictions range from $3.00 to $3.00. On average, they expect PDL BioPharma's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 18.6% from the stock's current price. View Analyst Price Targets for PDL BioPharma.
What is the consensus analysts' recommendation for PDL BioPharma?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PDL BioPharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PDL BioPharma.
Has PDL BioPharma been receiving favorable news coverage?
Headlines about PDLI stock have been trending positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PDL BioPharma earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days. View News Stories for PDL BioPharma.
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Aerie Pharmaceuticals (AERI), Alector (ALEC), NanoString Technologies (NSTG), Twist Bioscience (TWST), Rubius Therapeutics (RUBY), BAVARIAN NORDIC/S (BVNRY), Voyager Therapeutics (VYGR), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Vericel (VCEL), Atara Biotherapeutics (ATRA), MeiraGTx (MGTX), Cortexyme (CRTX), Osiris Therapeutics (OSIR) and GENFIT S A/ADR (GNFT).
What other stocks do shareholders of PDL BioPharma own?
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- Mr. Dominique P. Monnet, CEO, Pres & Director (Age 58)
- Mr. Peter S. Garcia, VP & CFO (Age 57)
- Mr. Christopher L. Stone, VP, Gen. Counsel & Sec. (Age 55)
- Mr. Nathan Kryszak, Deputy Gen. Counsel & Assistant Sec.
Who are PDL BioPharma's major shareholders?
PDL BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.68%), Vanguard Group Inc. (8.17%), Renaissance Technologies LLC (7.54%), Northern Trust Corp (4.06%), Connor Clark & Lunn Investment Management Ltd. (3.75%) and Brandes Investment Partners LP (3.65%). View Institutional Ownership Trends for PDL BioPharma.
Which institutional investors are selling PDL BioPharma stock?
PDLI stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BlackRock Inc., Bank of America Corp DE, Acadian Asset Management LLC, Prudential Financial Inc., AQR Capital Management LLC, Skandinaviska Enskilda Banken AB publ and Renaissance Technologies LLC. View Insider Buying and Selling for PDL BioPharma.
Which institutional investors are buying PDL BioPharma stock?
PDLI stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Chicago Equity Partners LLC, Charles Schwab Investment Management Inc., Paloma Partners Management Co, Crestline Management LP, KBC Group NV, AXA and Royal Bank of Canada. View Insider Buying and Selling for PDL BioPharma.
How do I buy shares of PDL BioPharma?
Shares of PDLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDLI stock can currently be purchased for approximately $2.53.
How big of a company is PDL BioPharma?
PDL BioPharma has a market capitalization of $288.93 million and generates $198.11 million in revenue each year. The biotechnology company earns $-68,860,000.00 in net income (profit) each year or $0.37 on an earnings per share basis. PDL BioPharma employs 105 workers across the globe.View Additional Information About PDL BioPharma.
What is PDL BioPharma's official website?
How can I contact PDL BioPharma?
PDL BioPharma's mailing address is 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV, 89451. The biotechnology company can be reached via phone at 775-832-8500 or via email at [email protected]
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)
MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe PDLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
